Farmak Presents New Hepatic Medicine - Hep-Art

The pharmaceutical company Farmak has supplemented its portfolio with a new brand - hepatic medicine Hep-Art. The drug is available as a lyophilisate solution for injection.

The new product of Farmak - Hep-Art contains an active substance ademetionine.

Ademetionine deficiency plays a key role in the hepatopathy. Reduced ademetionine level deteriorates the liver condition leading to inflammation and further to irreversible structural and degenerative changes in the liver.* Hep-Art eliminates deficiency of the endogenous ademetionine and stimulates its production in the body.

According to the instructions, it is indicated to treat:

intrahepatic cholestasis in adults, including patients with chronic hepatitis of various etiologies and cirrhosis; intrahepatic cholestasis of pregnancy; depressive syndromes.

 Olga Vereshchaka, Farmak Product Manager, "Hep-Art helps to restore the liver. Hep-Art acts as an antioxidant; it regenerates hepatic cells, and improves bile production and outflow. The triple action determines 7 effects of Hep-Art: choleretic, cholekinetic, antioxidant, detoxification, regeneration, neuroprotective,** antidepressant. Thus, we are able to treat patients with the intrahepatic cholestasis syndrome, getting improvement in their condition."

The drug is sold by prescription only.

Other news

Farmak JSC was inspected by HALMED, Croatian Regulatory Agency

HALMED, the Croatian Regulatory Agency, conducted a scheduled reinspection at Farmak JSC on 18-22 December 2017.

Farmak: 92 Years of Development

In historical terms, this is a period, for the Universe – just a moment. For Farmak JSC, this is a period of the Сompany’s development and transformation into up-to-date innovative business. Thanks to people, quality and innovative approaches, Farmak JSC is an example of domestic business, an industry driver, and the market leader* for the 7th year in a row. * based on sales volume in monetary terms according to Proxima Research in 2016.